A real-world study conducted across 9 European countries found that bolus injection frequency and engagement with a smart pen to administer insulin were associated with improved glycemic control among ...

ORLANDO -- For type 1 diabetes patients, switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) maintained glycemic control -- for those who used it as intended, the ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky for those with type 1 diabetes, the phase III QWINT-2 and -5 trials showed.

ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...

Most types of insulin therapy, an important part of diabetes treatment for many people, are given as daily injections to help manage blood sugar levels. Now, the maker of a once-weekly insulin ...

Insulin is an essential medicine that helps the body turn food into energy and regulate blood sugar levels for millions of people with diabetes nationwide. That makes access to insulin vital for ...

Please provide your email address to receive an email when new articles are posted on . Insulin efsitora alfa conferred noninferior HbA1c reductions vs. insulin degludec in two phase 3 trials. Level ...

MADRID — Eli Lilly's investigational once-weekly basal insulin analog efsitora alfa continues to show noninferiority to once-daily insulin in people with type 2 diabetes. However, in those with type 1 ...

Please provide your email address to receive an email when new articles are posted on . Change in HbA1c and hypoglycemia rates were similar between once-weekly basal insulin and once-daily insulin ...